Foundation Medicine Shows Sequencing-based Cancer Test Can ID Clinically Actionable Mutations
June 08, 2011
Foundation Medicine Shows Sequencing-based Cancer Test Can ID Clinically Actionable Mutations
The company, which has targeted the second quarter of 2012 for the commercial launch of its sequencing-based cancer test, demonstrated its performance on 75 cancer tissue samples from non-small cell lung cancer, melanoma, and colon cancer.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Entering NGS Space, Asuragen Launches Cancer Panels Optimized for FFPE on Ion Torrent and GA
January 4, 2012 / Clinical Sequencing News - Foundation Medicine Raises $10M, En Route to Launching Targeted Sequencing Test for Cancer Dx
August 24, 2011 / Clinical Sequencing News - Targeted Sequencing Panels Gaining Ground for Cancer Dx
August 17, 2011 / Clinical Sequencing News - UK Government Funding Development of Sequencing-Based Cancer Tests
June 21, 2011 / Clinical Sequencing News - Foundation Medicine, MSKCC to Develop Sequencing-based Blood Cancer Test from DNA, RNA
May 8, 2013 / Clinical Sequencing News